Rational Use of Topical Corticosteroids-noppadol230555

Embed Size (px)

DESCRIPTION

111

Citation preview

  • .

    1

    yCorticosteroids .. 2495y Hydrocortisone (eczematous dermatoses)

    2

  • Corticosteroidy y 4

    (hexane 3 pentane 1 )

    3

    Corticosteroidy (Ring structure) (Side chain)

    4

  • Corticosteroidy y yy

    5

    Structure of CorticosteroidsTriamcinolone acetonide Betamethasone dipropionate

    6

  • 7Mechanism of action

    8

  • Pharmacologyy (Anti-inflammatory effects)y (Immunosuppressive effects)y (Antiproliferative

    effects) : fibroblasts (collagen and ground substances)

    9

    Pharmacologyy (Vasoconstriction)

    histamine, bradykinins & prostaglandins

    10

  • Pharmacologyy (Vasoconstriction)

    Corticosteroids

    vasoconstrictor assay vasoconstriction test

    Corticosteroids 11

    vasoconstrictor assayy 5 mg

    9 12 y infrared reflection photometers /

    thermal conductivity / laser doppler velocimetry

    y metabolism 12

  • y 7

    ( 1 7 )y 4 mild,

    moderate, very potent, super potent

    13

    Class 1 superpotent Betamethasone

    dipropionate 0.05% Clobetasolpropionate 0.05%

    Diprotopointment/gel/lotion Dermovate cream

    Class 2 potent, upper mild strength

    Desoximetasone0.25% Mometasonefuroate 0.1%

    Topicort cream

    Elomet ointment

    Class 3 potent,upper mild strength

    Betamethasonevalerate 0.1

    14

  • Class 4 mild strength Fluocinolone

    acetonide 0.025% Mometasonefuroate 0.1% Prednicabate 0.1%

    Synalar ointment

    Elometcream/lotion Dermatop ointment

    Class 5 lower mild strength

    Triamcinoloneacetonide 0.1%

    15

    Class 6 mild strength Triamcinolone

    acetonide 0.02%Class 7 least strength

    Hydrocortisone 0.5,1,2.5% Prednisolone 0.5%

    16

  • Corticosteroids (chemical characteristics)9Fluticasone propionate : local

    adverse effect 9Mometasone furoate :

    17

    Corticosteroids (vehicles)9corticosteroid 9

    (ointment) (cream) (lotion)

    18

  • Corticosteroids (vehicles) : (ointment)9 (preservative) : 9 ( lichenification) 9

    19

    Corticosteroids (vehicles) : (cream)9 (intertriginous area)

    20

  • Corticosteroids (vehicles) : (lotion) (gel) (solution)9 9 alcohol propylene

    glycol / :

    21

    Corticosteroids (potency)9class 6-7 or low potency 9 class 2-5

    22

  • Corticosteroids9 corticosteroids 99 1

    23

    Corticosteroids9 atopic dermatitis 9 2 10

    24

  • Corticosteroids9 dyshidrosis lichen simplex chronicus 9 :

    25

    Corticosteroids9 / 300 potency 9 potency

    salicylic acid (occlusion)

    26

  • 1. / 2.

    3.

    4. 5. / 6. /7. / 8. / 9. 10.

    27

    0.1 % Triamcinolone acetonide cream

    0.1 % Triamcinolone acetonide lotion

    2

    28

  • 0.1 % Triamcinolone acetonide cream

    0.1 % Triamcinolone acetonide lotion

    29

    0.1 % Betamethasone valerate cream

    0.05 % Betamethasone dipropionate ointment

    2

    30

  • 0.1 % Betamethasone valerate cream

    0.05 % Betamethasone dipropionate ointment

    31

    PotencyyConcentrationy0.1 % Triamcinolone acetonideXy0.02 % Triamcinolone acetonide Y

    32

  • PotencyyDosage Form : yOintment is absorbed better than

    cream or lotiony0.1 % Mometasone furoate ointment Xy0.1 % Mometasone furoate cream Y

    33

    PotencyySalt of Drugy0.05 % Betamethasone dipropionate Xy0.1 % Betamethasone valerate Y

    34

  • yLow potencyyShort termy yRotational therapy

    35

    36

  • Side Effecty

    (local adverse effects)y (systemic reactions)

    37

    Side Effect local adverse effects (atrophic changes)y . . 2506 Triamcinolone

    acetonide y (epidermal atrophy) (alteration in

    skin elasticity) 38

  • Side Effect local adverse effects (atrophic changes)y / potency :

    39

    Side Effect local adverse effects (atrophic changes) :

    dermal atrophyy fibroblasts y collagen : 3 2

    40

  • Side Effect local adverse effects (atrophic changes) :

    dermal atrophyy 0.1% Betamethasone valerate 3 9 159

    (telangiectasia) (easy bruising) (purpura)

    41

    telangiectasia

    42

  • purpura easy bruising

    43

    Side Effect local adverse effects (hypopigmentation)y melanocyte : melanin

    44

  • Side Effect local adverse effectsy 16 43y (tinea versicolor) (tinea incognito) (onychomycosis) (herpes simplex infection) (molluscum contagiosum) (scabiasis)

    45

    Side Effect local adverse effects (acneiform reactions)y 3 9steroid acne9 (perioral dermatitis)9steroid rosacea

    46

  • Steroidacne

    47

    steroid rosacea

    48

  • perioral dermatitis

    49

    Side Effect local adverse effects (acneiform reactions)y perioral dermatitis & steroid rosacea99

    (rebound phenomenon) 9

    (tachyphylaxis) 50

  • Side Effect local adverse effects (acneiform reactions)ysteroid acne9 (acne vulgaris) 9 9

    51

    Side Effect local adverse effectsy corticosteroid (glaucoma)y (vision loss)y corticosteroid 300

    52

  • Tachyphylaxisy corticosteroids

    53

    Steroid additiony corticosteroidsy high potenty y rosacea telangiectasis

    54

  • corticosteroidsy y 0.2 6y corticosteroid

    55

    corticosteroids Parabens Isopropyl palmitatePropylene glycol Polysorbate 60Benzyl alcohol Stearyl alcoholChlorocresol CorticosteroidEthylenediamine HCl Antibiotics

    56

  • Side Effect Systemic effectsy corticosteroid :9High potency clobetasol propionate 0.05% 2 g/day 2 3 9Medium potency 7 g/day 2 weeks

    57

    Side Effect Systemic effectsy 9 /9 : 9 9 potency of corticosteroids

    58

  • Side Effect Systemic effects y 9 9

    59

    9 1 (fingertip

    units) 9 1 fingertip units : male = 0.49 g female = 0.43 g

    60

  • 1 fingertip units

    61

    9 Rule of hand9 1 1 g9 1 2

    62

  • 9 corticosteroids class 1 3 1 2 : 1 tachyphylaxis9corticosteroids class 4 7 2

    63

    9 corticosteroids High potency : 2 weeks9corticosteroids Medium/Low potency : 3 months

    64

  • 9 corticosteroids Low potency : 2 weeks9 1 side effects 2.5 3 & drug metabolism

    65

    9Systemic side effects 9 9 Adrenal crisis9

    66

  • 9 FDA USA .. 2530 25409 Betamethasone 79.4 ( 25.7 Betamethasone dipropionate + Clotrimazole)

    67

    9 Conchrane database 9 //9 class 1

    68

  • 9 C 9 pregnancy category C9 :

    69

    y Tar: 3-10 % LCD

    (Liguor Carbonis Detergents)y 3-5%CCT (Crude Coal Tar)

    70

  • (Topical therapy)1. Corticosteroids 2. Tar 3. Dithranol (Anthralin) 4. Calcipotriol 5. Salicylic acid

    71

    CoalTar

    72

  • (Tars) y DNA y y

    73

    Tar Shampooy20 %Coal Tar Shampooy Olive oily

    74

  • Scalp Lotiony0.02 % TA LotionyDesoximetasone yMometasone lotion

    75

    Combination with Coal TaryTreatment PsoriasisyCoal Tar + corticosteroidy5 % LCD in 0.02 % TAy5 % LCD in 0.1 % Bet.

    Valeratey5 % LCD in 0.05 % Bet.

    valerate

    76

  • Tar + Corticosteroidy5 % LCD creamy5 % LCD in 0.02 % TAy 5 % LCD in 0.05 % Bet. Valeratey 5 % LCD in 0.1 % Bet. Valeratey //

    (genital area) 77

    EmollientyCream baseyLiquid paraffin

    (Mineral oil)yPetroleum jelly

    (Vaseline)

    78

  • Keratolytic agenty 3 - 10 % salicylic acidy 3 - 10 % urea creamy combind with

    corticosteroid

    79

    Combination with UreayTreatment for Dry skiny10 % Urea in 0.02 % TAy10 % Urea in 0.1 % Bet.

    Valeratey20 % Urea ointmenty40 % Urea ointment

    80

  • Keratolytic agentSalicylic acid Urea

    y 3 % SA in 0.02 % TAy 5 % SA in 0.02 % TAy 10 % SA in 0.02 % TAy 10 % SA ointmenty 20 % SA ointment

    y10 , 20 % Urea y 10 % Urea in 0.02 % TAy 10 % Urea in 0.05 %

    Bet.valeratey 10 % Urea in 0.1 %

    Bet.valerate81

    Combination with Antibiotic agentyClioquinol

    (Iodochlorhydroxyquin)yantibiotic that works by

    preventing the growth of fungus/bacteriay3 % Vioform in 0.02 %

    TA82

  • Calcipotriol y y differentiation y

    83

    Calcipotriol y 3 , y 50 /

    84

  • VitamineD3Analogues

    85

    Fucidicacid

    86

  • First line drug Second line drug

    yMethotrexate 5-25 ./ 3 12 . (triple dose therapy) y Retinoid:- acitretin 0.25-1 ././

    y Cyclosporin 3 5 ././ 1 - 2 / (2 divided dose)

    87

    Methotrexate

    2.5 . 88

  • 89

    Methotrexatey Dihydrofolate reductase DNA y y y

    90

  • MethotrexateyPsoriatic erythroderma yPustular psoriasis yPsoriasis ySevere plaque type psoriasis yPsoriatic arthritis

    91

    Methotrexatey 2.5-25 . y 3 12 y 2.5-5 . 1 2

    92

  • Methotrexate 2.5 mg take 1 : 1 : 1

    Monday 08.00 AM 1 Tab

    Monday 08.00 PM 1 Tab

    Tuesday 08.00 AM 1 Tab

    Begin on Monday morning

    93

    Methotrexate 2.5 mg take 2 : 2 : 1

    Wednesday 08.00 PM 2 Tab

    Thursday 08.00 AM 2 Tab

    Thursday 08.00 PM 1 Tab

    Begin on Wednesday evening

    94

  • Methotrexate1.2.23.4.5.6.7. MTX

    MTX 12 8.

    95

    1. complete blood count2. BUN3. creatinine4. liver function test

    yy y 1-3

    96

  • y HIV Immunosuppression y y 1.52 g liver biopsy liver biopsy liver biopsy 1 . y 3

    97

    SideEffectofMTXy y y y y

    98

  • SideEffectofMTXy (nephropathy) y y y (reactivation of sunburn response)

    99

    DrugInteractionofMTXy methotrexate alcohol, salicylates, cotrimoxazole, trimethoprim, probenecid, phenytoin, retinoids, pyrimethamine furosemide

    100

  • Acitretin25mg

    101

    y y differentiation y CMI HMI y

    102

  • 1. Pustular psoriasis 2. Extensive plaque type psoriasis

    3. Erythrodermic psoriasis

    103

    yAcitretin 0.5 - 1 ././ 0.25 - 0.5 ././ 3

    104

  • y () y complete blood count,

    liver function test, cholesterol, Triglyceride, HDL yPregnancy test

    105

    y liver function test 1 - 3 y triglyceride

    106

  • SideEffectyCheilitis (100%), , ,

    (20-50%), (100%), , (bruising), , (20%), ,

    107

    SideEffecty y y y (teratogenicity) 3

    108

  • y y ( 3 ) y

    109

    y liver function test y y tetracycline ( intracranial hypertension) phenytoin (competition of plasma-protein binding)

    110

  • H1receptorantagonistsShortActing LongActing

    yChlorpheniramineyHydroxyzine

    yCetirizineyLoratadiney DesloratadineyLevocetirizine

    111

    H1-receptor antagonistsCPM Details

    yShort ActingySedative side effectyMost common use 1

    tab hs

    112

  • H1-receptor antagonistsHydroxyzine 10 mg Details

    yShort ActingySedative side effectyMost common use 1

    tab hs

    113

    H1-receptor antagonistsyCetirizineyLoratadineyLong Actingy1 tab OD

    114

  • 115

    Topical Retinoids Retinol, Retinoic acid, Isotretinoin, Adapalene

    116

  • Topical Retinoids* * * Glycosaminoglycan *

    117

    Topical Retinoids *

    118

  • Topical Retinoids* * * *

    119

    Topical Retinoids* Oral Retinoids * Topical Retinoids * , 120

  • 121

    122

  • * Carboxylic acid hydroxy alpha * AHA

    123

    * * * * * *

    124

  • * AHA 4-30% ( AHA 3-10%) * AHA 50%

    125

    126

  • Salicylic acid

    AHA BHA

    127

    * AHA * Salicylic acid 128

  • * alpha-helical peptide chains 3 *

    129

    * *

    130

  • 1. (melanocytes)2. 3. tyrosinase

    131

    4. melanosome malpighian cell phacocytosis melanocytic dendrite

    5. melanosome oxidized form () reduced form ()

    132

  • 1. (opacifying or covering agent) 2. (depigmentating agent) tyrosinase

    133

    3. (sunscreen agent) UV

    4. (oxidizing agent)

    134

  • - alpha hydroxy acid (AHA) -

    135

    Hydroquinone

    - 3 - 5 % Hydroquinone- -

    136

  • Azelaic acid- - tyrosinase 137

    Azelaicacid

    138

  • Arbutin- hydroquinone glycoside Bergenia crassifolia Arctostaphylos uvaursi - tyrosinase hydroquinone

    139

    - magnesium ascorbyl phosphate , sodium ascorbyl phosphate sodium ascorbyl sulfate - ascorbyl dipalmitate , ascorbyl glucosamine - gamma-ascorbic acid phosphatase 140

  • Lactic acid - Lactic acid tyrosinase - 5 20 % -

    141

    (UV)y UV- A

    y UV - B sunburn

    142

  • y 10.00 - 15.00 . y

    143

    y y UV UV UVA

    144

  • y ySPF SunProtectionFactor UVB SPF15,30

    145

    SPF15 y 30 y SPF 15 15 30 7

    146

  • ???

    147

    y 1y 2 y

    148

  • SunProtectionProduct

    149

    150